Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Birrer

Showing results (171-180 of 222) with videos related to

Pageof 23
Sort By:
The Lancet. Oncology|August 7, 2021
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trialBradley J Monk, Nicoletta Colombo, Amit M Oza, et al.
The Lancet. Oncology|September 3, 2019
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trialMansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J Birrer, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 19, 2012
Common variation in Nemo-like kinase is associated with risk of ovarian cancerKristen N Stevens, Linda E Kelemen, Xianshu Wang, et al.
Gynecologic Oncology|September 23, 2017
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group studyKathleen N Moore, David Tritchler, Kenneth M Kaufman, et al.
Mucosal Immunology|June 6, 2024
Metabolically active neutrophils represent a permissive niche for Mycobacterium tuberculosisJ Tucker Andrews, Zijing Zhang, G V R Krishna Prasad, et al.
Oncotarget|November 18, 2015
Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancerKim Moran-Jones, Brian S Gloss, Rajmohan Murali, et al.
Gynecologic Oncology|May 24, 2017
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group studyHenry D Reyes, Jeffrey Miecznikowski, Jesus Gonzalez-Bosquet, et al.
Plos One|December 6, 2011
Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft modelChristopher K McCann, Whitfield B Growdon, Kashmira Kulkarni-Datar, et al.
Plos One|February 23, 2012
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcomeDavid A Engler, Sumeet Gupta, Whitfield B Growdon, et al.
Oncotarget|October 3, 2015
A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancerEdward J Richards, Jennifer Permuth-Wey, Yajuan Li, et al.
Pageof 23

Showing results (171-180 of 222) with videos related to

Sort By:
Pageof 23
The Lancet. Oncology|August 7, 2021
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trialBradley J Monk, Nicoletta Colombo, Amit M Oza, et al.
The Lancet. Oncology|September 3, 2019
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trialMansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J Birrer, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 19, 2012
Common variation in Nemo-like kinase is associated with risk of ovarian cancerKristen N Stevens, Linda E Kelemen, Xianshu Wang, et al.
Gynecologic Oncology|September 23, 2017
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group studyKathleen N Moore, David Tritchler, Kenneth M Kaufman, et al.
Mucosal Immunology|June 6, 2024
Metabolically active neutrophils represent a permissive niche for Mycobacterium tuberculosisJ Tucker Andrews, Zijing Zhang, G V R Krishna Prasad, et al.
Oncotarget|November 18, 2015
Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancerKim Moran-Jones, Brian S Gloss, Rajmohan Murali, et al.
Gynecologic Oncology|May 24, 2017
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group studyHenry D Reyes, Jeffrey Miecznikowski, Jesus Gonzalez-Bosquet, et al.
Plos One|December 6, 2011
Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft modelChristopher K McCann, Whitfield B Growdon, Kashmira Kulkarni-Datar, et al.
Plos One|February 23, 2012
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcomeDavid A Engler, Sumeet Gupta, Whitfield B Growdon, et al.
Oncotarget|October 3, 2015
A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancerEdward J Richards, Jennifer Permuth-Wey, Yajuan Li, et al.
Pageof 23